Interactions between tumor cells and cancer-associated fibroblasts (CAFs) in the tumor microenvironment significantly influence cancer growth and metastasis. Transforming growth factor-β (TGF-β) is known to be a critical mediator of the CAF phenotype, and osteopontin (OPN) expression in tumors is associated with more aggressive phenotypes and poor patient outcomes. The potential link between these two pathways has not been previously addressed. Utilizing in vitro studies using human mesenchymal stem cells (MSCs) and MDA-MB231 (OPN+) and MCF7 (OPN − ) human breast cancer cell lines, we demonstrate that OPN induces integrin-dependent MSC expression of TGF-β1 to mediate adoption of the CAF phenotype. This OPN-TGF-β1 pathway requires the transcription factor, myeloid zinc finger 1 (MZF1). In vivo studies with xenotransplant models in NOD-scid mice showed that OPN expression increases cancer growth and metastasis by mediating MSC-to-CAF transformation in a process that is MZF1 and TGF-β1 dependent. We conclude that tumor-derived OPN engenders MSC-to-CAF transformation in the microenvironment to promote tumor growth and metastasis via the OPN-MZF1-TGF-β1 pathway.
INTRODUCTION
Tumor growth and metastasis is highly dependent on complex dynamic interactions between cancer cells and tumor stroma, mediated by direct cell-cell contact and secreted growth factors and cytokines. Cancer-associated fibroblasts (CAFs), a tumor stromal element, are involved in tumor growth potentiation, extracellular matrix degradation, tumor cell motility, inhibition of host anti-tumor response, promotion of angiogenesis and metastasis. CAF origin is likely multifactorial, derived from local fibroblasts, bone marrow mesenchymal stem cells (BM-MSCs), pericytes and tumor cells. Defining molecular markers and the signal pathways that mediate CAF activation are poorly understood. Nevertheless, it is generally accepted that α-smooth muscle actin (SMA), tenascin-C, vimentin and fibroblast-specific protein-1 (FSP-1), among others, describe the CAF phenotype. 1, 2 In addition, transforming growth factor (TGF)-β is critical for CAF activation and elaboration of a pro-tumorigenic microenvironment. [3] [4] [5] [6] Signaling by TGF-β regulates tumor initiation, progression and metastasis through tumor cell-autonomous and host-tumor interactions.
Osteopontin (OPN), a phosphoprotein secreted by malignant cells and tumor stromal cells, is a key mediator of tumor cell migration and metastasis and a marker of breast cancer progression and metastasis. [7] [8] [9] [10] [11] [12] [13] Recent findings suggest that tumor-derived OPN instigates BM-derived MSC trafficking to the tumor microenvironment, [14] [15] [16] which is characterized by the outgrowth of a desmoplastic stroma rich in CAFs that promotes cancer growth and metastasis. 14, 15, 17 However, a direct relationship between OPN and the CAF phenotype has never been described.
In this study, with in vitro and in vivo human breast cancer models, we demonstrate that OPN induces MSC-to-CAF transformation. OPN binds to cell-surface integrin receptors to activate the transcription factor, myeloid zinc finger 1 (MZF1) and induce the MSC production of TGF-β1. The adoption of the CAF phenotype is associated with increased local tumor growth and metastases. Aptamer (APT) blockade of OPN abolishes this MZF1-TGF-β1-mediated MSC-to-CAF transformation. This pathway has not been previously characterized. at 12 h. At all time intervals, except TGF-β3 at 96 h, the increase was significant from baseline (P o 0.05). Further studies used the 48-h time point.
OPN-mediated TGF-β expression requires integrin cell-surface receptors OPN binds to αvβ3 integrin and CD44 receptors to mediate important cell-cell and cell-matrix signaling pathways. 18 To examine the role of these cell-surface receptor pathways in OPN-mediated TGF-β expression, MSCs were exposed to OPN and the following inhibitors: RGD, an integrin competitive ligand inhibitor, αvβ3 integrin Ab, CD44 Ab, or APT; control inhibitors: RGE, immunoglobulin G (IgG), and MuAPT (Figure 1c ). Extracellular binding of OPN by APT and blockade of integrin and CD44 receptors ablated OPN-mediated active TGF-β1, -β2 and -β3 expression (P o0.01 vs OPN). The control inhibitors did not alter TGF-β expression. Pharmacological inhibition of canonical integrin signaling pathways, Src(PP2;10 μM) or FAK(PF228;10 μM), abolished OPN-mediated TGF-β expression (data not shown). These results indicate that OPN-mediated TGF-β expression in MSCs requires OPN binding to integrin receptors, and to a lesser extent, CD44 receptors.
As TGF-β1 expression is upregulated to a larger degree than other isoforms, remaining studies focus on TGF-β1. A similar expression pattern was seen in total TGF-β1 after OPN exposure (Figure 1d ). APT blockade of OPN and integrin receptor blockade resulted in a significant decrease in total TGF-β1 expression (P o 0.01). However, CD44 receptor blockade had no effect. These results indicate that the primary receptor involved in OPN-mediated TGF-β1 expression in MSCs is likely integrin.
MSC CAF marker expression is OPN-mediated
Expression of OPN-mediated CAF marker (SMA, tenascin-C, vimentin and FSP-1) mRNA was significantly ablated by APT and RGD (P o 0.01 vs OPN, OPN+MuAPT and OPN+RGE) ( Figure 2a ). Of note, on light microscopy, after OPN treatment, MSCs become more elongated and spindle shaped. Functional correlation using composite zymography demonstrated that OPN increased MSCassociated matrix metalloproteinase 2 (MMP2) and MMP9 activities by eightfold and fivefold, respectively (Figure 2b ). APT and RGD blocked these increases. OPN increased MSC adhesion and migration/invasion by fivefold and twofold, respectively (P o 0.01 OPN vs untreated MSCs; Figure 2c ). APT, RGD and αvβ3 integrin Ab decreased adhesion and migration/invasion to baseline. These data indicate that OPN-integrin interactions in MSCs increase CAF marker expression, MMP activity, adhesion and migration/invasion. MSCs were exposed to OPN once or daily for 1 week to determine the duration of CAF marker and TGF-β1 expression. At 2 days, all CAF markers and TGF-β1 were elevated by 8-12-fold in both the groups (P o0.01). In the group exposed once, all CAF markers and TGF-β1 were decreased by day 7 (P o0.05). In the daily exposure group, by day 5, TGF-β1 was elevated even further (P o 0.05). By day 7, tenascin-C and TGF-β1 were elevated compared with day 2 (P o0.05; Figure 2d ). These results indicate that under continuous OPN stimulation, as would likely occur in an (a) Concentration-dependent expression in MSCs following exposure to OPN for 48 h (ANOVA P = 0.0001). (b) Time-dependent expression in MSCs following exposure to OPN (180 ng/ml). (c) Active TGF-β1, -β2 and -β3 protein expression in MSCs exposed to OPN (180 ng/ml for 48 h) and one of the following inhibitors: RGD, αvβ3 integrin Ab, CD44 Ab or APT. Control inhibitors: RGE, IgG and MuAPT (*Po 0.01 vs no treatment; **P o0.01 vs OPN). (d) Total TGF-β1 protein expression in MSCs exposed to OPN (180 ng/ml for 48 h) (*P o0.01 vs no treatment; **P o0.01 vs OPN).
OPN-producing tumor microenvironment, a robust and durable CAF marker profile persists and TGF-β1 expression is upregulated to a similar/larger degree.
To determine the functional role of TGF-β1, its' signaling was blocked using a TGF-β1 type I receptor inhibitor (SB4) or TGF-β1 type II receptor shRNA. OPN-stimulated CAF marker expression was ablated (P o 0.01 vs OPN; Figure 2e ). In selected instances, exogenous recombinant TGF-β1 (400 pg/ml) was administered. 19 Exogenous TGF-β1 restored CAF marker expression in OPN+APT +TGF-β1 (P o0.01 vs OPN+APT).
BM-MSCs (3000 cells), enriched from normal human BM, were exposed to OPN. Active TGF-β1 protein increased approximately sevenfold (P o0.01), and total:active TGF-β1 ratio was~8-10:1 (data not shown). OPN significantly increased CAF marker mRNA expression, which was blocked by RGD and APT (P o0.01 vs OPN) ( Figure 2f ). Human skin, mammary and lung fibroblasts and murine embryonic fibroblasts were exposed to human OPN. Active TGF-β1 protein and CAF marker expression was not altered (data not shown). In summary, OPN-integrin binding induces TGF-β1 and CAF marker expression in MSCs.
OPN activates TGF-β1 transcription via MZF1
The role of OPN in TGF-β1 transcriptional regulation was determined by measuring the recruitment of RNA polymerase II to a consensus TATA box (ATTA located at − 1195 bp) 20 and the final exon. TGF-β1 transcription increased~20-fold after OPN exposure (P o 0.01; Figure 3a) . A full-length human TGF-β1 promoter (−3360/+124) was amplified ( Figure 3b ). 21 Stimulation with OPN resulted in 435-fold transactivation with lesser activation of the first two deletion constructs ( Figure 3c ). The remaining three deletion constructs showed no activation after OPN stimulation. The 67-bp region (−691 to − 624) contained a canonical binding site for MZF1 (GGGGAGGAGGGGGA), as predicted by TFSearch. 22, 23 Two MZF1 consensus DNA-binding sequences have been identified: 5′-AGTGGGGA-3′ and 5′-CGGGGAGGGGGAA-3′ (Figure 3d ). This G-rich region is 100% homologous to the mouse TGF-β1 promoter (−653 to − 637). Human and mouse MZF1 proteins are 83% homologous. MZF1 is involved in cell differentiation, migration and proliferation. [24] [25] [26] [27] Chromatin immunoprecipitation (ChIP) assays targeting − 697 to − 600 bp confirmed binding of MZF1 and RNA polymerase II to the TGF-β1 promoter in the presence of OPN (Figure 3e ). After OPN exposure, MZF1 binding to the G-rich promoter region increased~18-fold (P o 0.02 vs MSCs). This putative MZF1-binding site was mutated to generate two single mutants and one double mutant ( Figure 3d ). All mutation constructs demonstrated a significant decrease in luciferase activity (P o0.03; Figure 3f ). siRNA-mediated silencing of MZF1 significantly decreased TGF-β1 full-length promoter luciferase activity (P o0.01), MZF1 and TGF-β1 mRNA (P o 0.01) and active TGF-β1 protein expression (P o 0.02) in OPN-stimulated MSCs compared with controls ( Figure 3g ). Taken together, these data indicate that MZF1 regulates OPN-mediated TGF-β1 transcription and protein expression.
OPN induces TGF-β1-dependent MSC CAF marker expression in breast cancer co-cultures MSCs were co-cultured in Boyden chambers with MB231 (OPN+) or MCF7 (OPN − ) human breast cancer cells. All enzyme-linked immunosorbent assay and quantitative real-time PCR (qRT-PCR) data presented below are results of media from MSC well or MSC cell lysates only. OPN+ cells exhibit aggressive in vitro indices of adhesion and migration/invasion. OPN − cells exhibit the opposite. 28, 29 MSCs do not express OPN (data not shown). After 24 h, in MB231+MSC, active TGF-β1 increased ninefold compared with baseline; blockade by αvβ3 Ab, RGD and APT abolished the TGF-β1 response (P o0.01). Conversely, in MCF7+MSC, active TGF-β1 expression was minimal. Addition of OPN increased active TGF-β1 approximately sevenfold; this was blocked by αvβ3 Ab, RGD and APT (Po 0.01; Figures 4a and b) . In co-culture with MB231, CAF marker and TGF-β1 mRNA expression increased 20-30-fold (P o 0.01); abolished by APT, αvβ3 Ab and RGD (P o 0.01); indicating a causative role for OPN-integrin binding. As expected, exogenous OPN significantly increased CAF marker and TGF-β1 mRNA expression in an integrin-dependent manner (Figures 4c and d) .
Co-culture studies were repeated with SB4, shTGFβR2 and exogenous TGF-β1 ( Figure 4e ). 19 CAF markers in MB231+MSC were significantly decreased with APT and reversed with exogenous TGF-β1. Similarly, TGF-β1 receptor blockade ablated CAF marker expression (P o 0.01). These data indicate that tumorderived OPN interacts with MSC integrin receptors to induce TGF-β1-dependent CAF marker expression. APT blockade of OPN in MB231 co-culture significantly decreased MZF1 mRNA while ablating MZF1 and RNA polymerase II binding to the TGF-β1 promoter region. Conversely, co-culture with MCF7 did not express MZF1 mRNA without exogenous OPN (Figures 4f and g) . In parallel with our previous results, these data suggest that OPN mediates MZF1-dependent TGF-β1 expression to induce CAF marker expression in MSCs.
MZF1 and TGF-β1 expression in mouse models
In a MB231+MSC orthotopic xenotransplant model, we previously demonstrated that extracellular OPN blockade and inactivation by APT significantly inhibits: (1) local breast cancer growth and metastasis and (2) MSC expression of CAF markers. 17 This mouse model was repeated to study the TGF-β1 and MZF1 expression. Animals were injected via tail vein with APT or MuAPT every 2 days and imaged for 8 weeks. Bioluminescence was greater by 10-fold in MB231+MSC compared with MB231 (P o 0.01; Figure 5a ). Local tumor growth showed the same pattern as our original study (data not shown). 17 At 8 weeks, MSCs were isolated from primary tumors and metastatic sites. In MB231+MSC, MZF1 and TGF-β1 mRNA increased by fourfold and eightfold, respectively, in all the locations (P o 0.01); expression ablated by APT (Figures 5b and c) . As expected, CAF markers were readily expressed but ablated in the presence of APT (data not shown).
We have previously reported OPN-mediated EMT (epithelialmesenchymal transition) associated growth of hepatocellular cancer in a mouse xenograft model. 30 To ascertain the role of our newly proposed OPN-MZF1-TGF-β1 axis in hepatocellular cancer, qRT-PCR was performed using cDNA from MSCs isolated by fluorescence-activated cell sorter (FACS) from the primary liver tumors of SK-Hep1+MSC xenografts. APT blockade significantly decreased OPN, MZF1, TGF-β1 and SMA mRNA expression (P o 0.01), supporting the likely presence of the OPN-MZF1-TGF-β1 axis in hepatocellular cancer (Figure 5d ).
A series of xenotransplant experiments was performed using dual-labeled MCF7 cells that constitutively express OPN (red fluorescent protein (RFP)-luc-MCF7-lvOPN) implanted alone or coimplanted with green fluorescent protein (GFP)-MSCs. A subset of GFP-MSCs had constitutive MZF1 knockdown (MSC(dMZF1)). When MCF7-lvOPN were implanted alone, increased growth did not occur until 8 weeks. In MCF7-lvOPN+MSC mice, tumor growth was significantly greater. Deletion of MZF1 resulted in abrogation of OPN-associated tumor growth in MCF7-lvOPN. In a similar manner, APT treatment resulted in ablation of tumor growth in MCF7-lvOPN+MSC mice (Figure 6a To elucidate the role of TGF-β1, exogenous TGF-β1 (1.2 ng/ mouse/day via tail vein) was administered to a subgroup of MCF7-lvOPN+MSC(dMZF1). 31 With this gain-of-function study bypassing the inhibition of MSC elaboration of TGF-β1 in MSC(dMZF1)s, exogenous systemic TGF-β1 accelerated growth and metastasis (Figures 7a and b) . At Week 5, luciferase activity was enhanced 10-fold with TGF-β1 (P o 0.01). Primary tumor MSC(dMZF1)s were isolated by FACS after 6 weeks. CAF markers were strongly expressed with exogenous TGF-β1; MZF1 was not expressed; TGF-β1 was expressed in a positive feedback manner (Figures 7c and  d) . 19 These results indicate that OPN mediates MZF1-dependent TGF-β1 expression in MSCs to promote local tumor growth and metastases via MSC-to-CAF transformation.
Immunohistochemistry of human breast cancer
Immunohistochemical staining of normal breast (n = 2), ER+PR+ breast cancer (n = 2) and triple-negative breast cancer (TNBC) (n = 4) tissue samples, obtained under the Institutional Review Board's (IRB) approval by a collaborative researcher, was performed to assess the correlation of OPN, TGF-β1, MZF1 and SMA expression. When comparing normal and ER+PR+ (luminal) breast tissue to TNBC, basal-like thus histologically similar to MB231, there is a definite difference in quantity and intensity of staining of these proteins (Figure 8 ). In addition to the expected higher-grade phenotypic features (minimal tubule formation and enlarged nuclear size and pleomorphism), the aggressive, poorer prognosis TNBC displays increased cytosolic expression of all the four proteins in the tumor cells and stromal elements. In TNBC, the quantity of nuclear staining of MZF1 is also increased. The data obtained from this limited immunohistochemical analysis are not enough to draw any conclusion regarding the prognostic value of the OPN-MZF1-TGF-β1 axis, but it does pave the way for future studies to examine this more closely. This would add to the current data supporting OPN as a prognostic marker for breast cancer. 32, 33 
DISCUSSION
The tumor microenvironment significantly influences tumor behavior. 6, [34] [35] [36] [37] CAFs are a critical constituent, residing within the tumor or its margins. However, there is lack of an accepted biomarker definition and controversy over the cell of origin and location of the CAF precursor cell. 1, 35, 38, 39 Utilizing in vitro and in vivo models of human breast cancer, we demonstrated that: (1) OPN induces MZF1-dependent TGF-β1 production in MSCs to promote local tumor growth and metastasis, (2) MSCs adopt a CAF phenotype as the result of autocrine TGF-β1 signaling, and (3) inactivation of extracellular OPN by the OPN-R3 APT blocks TGF-β1-mediated MSC-to-CAF transformation and tumor growth and metastasis. The OPN-MZF1-TGF-β1 signaling pathway has not been previously described.
CAFs are specialized stromal cells with myofibroblast features that promote in vitro cell proliferation, in vivo tumor growth and facilitate by producing tumor-promoting cytokines, such as C-C motif chemokine ligand 5, tumor necrosis factor, interleukin-6 and stromal cell-derived factor-1. 40, 41 Additionally, CAFs might be a critical niche component, protecting cancer stem cells, a small proportion of cancer cells responsible for cancer metastasis, drug resistance and disease relapse, from the effects of chemotherapy. Small numbers of MSCs, multipotent cells primarily located in BM, can be detected in other tissues where they may serve as sources of dormant stem cells. [42] [43] [44] [45] Data from animal and human breast cancer models suggest that a significant proportion of CAFs are derived from circulating BM-derived MSCs. 46, 47 Thus eliminating CAFs and/or repressing the generation of CAFs from local and BMderived MSCs might be an effective therapeutic strategy against cancer, especially in combination with standard chemotherapy.
OPN is a ligand for αvβ3 integrin and CD44 receptors. 18, 48, 49 Elevated plasma OPN correlates with increased breast cancer tumor burden, metastasis and prognosis. 11,50-52 OPN inhibition decreases local breast cancer growth and metastasis. 17, 28, 29, [53] [54] [55] Therefore OPN has been proposed as an anti-cancer target. Studies suggest that OPN-integrin binding via the RGD domain stimulates tumor cell invasiveness and migration, in part through activation of MMPs/urokinase plasminogen activator. On-going research in our laboratory has identified the likely involvement of protein kinase A signaling in the OPN-MZF1-TGF-β1 axis. Our current hypothesis is that protein kinase A is activated downstream of integrin, which then leads to MZF1 upregulation. Further experiments are underway to test this hypothesis. OPN binds to CD44 to promote cell survival, chemotaxis, homing and adhesion to enhance metastatic behavior, suggesting a direct effect of OPN on tumor cells. [56] [57] [58] Immunohistochemical studies demonstrate that OPN localizes to the leading edge of invading tumors, which are enriched in MSC-like cells, suggesting that OPN+ cells interact in a paracrine manner with tumor microenvironment constituents. [59] [60] [61] In animal models, OPN produced by tumor and stromal cells stimulates the incorporation of activated BM-derived cells into breast tumors, instigating local growth and distant metastases. 14, 62 Large numbers of BM-MSCs were found in explanted tumors and metastases as shown by GFP+ BM transplantation studies. By description, this is similar to our findings. 17 In xenograft studies with 4T1(OPN+) murine breast cancer cells (spontaneous metastatic model), 63 MSCs injected into circulating blood selectively localized and proliferated in subcutaneous and metastatic sites. However, the signaling pathways that underlie OPN-induced MSC accumulation in tumors remain unknown.
TGF-β mediates fibroblast differentiation, tumor stroma formation and regulates all stages of tumor development via tumor cellautonomous and host-tumor interactions. [3] [4] [5] [6] Resident fibroblasts and BM-derived MSCs convert into CAFs during tumor progression, a TGF-β autocrine/paracrine signaling loop acts to initiate/ maintain this CAF phenotype and CAFs increase tumor invasion. 19, [64] [65] [66] The loss of TGF-β1 reverses the growth advantage imparted by CAFs. 67 These studies demonstrated the role of TGF-β signaling in CAF initiation and maintenance. However, the initiating steps for TGF-β synthesis have never been addressed. Serendipitously, OPN induces TGF-β expression and fibroblast activation in models of inflammation and fibrosis. [68] [69] [70] [71] [72] [73] [74] [75] In the context of carcinogenesis, our findings indicate that tumorderived OPN stimulates TGF-β1 production and subsequently the CAF phenotype in MSCs. MZF1, originally isolated from a myelogenous leukemia patient, is a Kruppel family transcription factor containing 13 C 2 H 2 zinc fingers. MZF1 forms a peptide loop that binds to G-rich DNA consensus sequences. 22, 23, 27 Genes regulated by MZF1 identified thus far include: CD34, lactoferrin, myeloperoxidase, PADI1 and N-cadherin. 76 A few reports identify MZF1 as a tumor suppressor, namely an in vitro cervical cancer model 24 and an in vivo knockout model; 27 however, the majority of recent literature supports the oncogenic nature of MZF1 we describe. 23, 25, 26, 76, 77 Expression of MZF1 is associated with the anti-apoptotic and oncogenic transformation of cervical (SiHA, HeLa) and colorectal (Rko, SW480) cancer cell lines. 76 3T3 cells transduced with MZF1 lose contact inhibition and substrate dependence, while undergoing more rapid cell cycling; in athymic mice, these transduced 3T3 cells form aggressive fibrosarcomas. 23 An MZF1 antisense oligonucleotide inhibits PKCα expression and decreases cell migration and invasion in hepatocellular cancer (SK-Hep1). 77 The role of MZF1 in TGF-β1 expression has never been described, but the link to N-cadherin and the overlap between EMT and CAF markers correlates with the role of MZF1 in MSC-to-CAF transformation. RNA APTs are short ssRNA oligonucleotides that specifically bind extracellular protein targets, such as OPN. 78, 79 APTs possess many useful properties as potential therapeutic molecules: they are small (8-15 kD) synthetic compounds with high target affinity (K d~0 .05-10 nM), are heat stable, site-specific modifications can be made to alter bioavailability and mode of clearance and have minimal interbatch variability. Animal studies have shown that APTs are well tolerated, exhibit little immunogenicity and are likely suitable for repeated administration. 78, 79 The APT pegaptanib was approved for treatment of macular degeneration. 80 Our work indicates that OPN-R3 APT may serve a role in targeting CAF phenotype activation.
In summary, we have characterized a signaling pathway by which OPN interacts with MSCs via integrin receptors to upregulate MZF1-mediated expression of TGF-β1, which results in conversion of MSCs to a CAF phenotype with promotion of more aggressive local tumor growth and metastasis. Blockade and inactivation of extracellular OPN by the OPN-R3 APT effectively abolishes this pathway. This suggests that OPN blockade may be an effective clinical strategy for tumor growth inhibition.
MATERIALS AND METHODS Materials
The pharmacological properties and sequences of OPN-R3 APT and mutant APT (MuAPT) have been previously published. 28 Recombinant human OPN and TGF-β1 proteins (R&D Systems, Minneapolis, MN, USA); αvβ3 integrin and CD44 Abs (Santa Cruz Biotechnology, Santa Cruz, CA, USA); Arg-Gly-Asp (RGD), Arg-Gly-Glu (RGE) (Sigma-Aldrich, St Louis, MO, USA); SB431542 a TGF-β1 type I receptor inhibitor (EMD Millipore, Billerica, MA, USA); TGF-β1 type II receptor shRNA (Santa Cruz Biotechnology); MZF1 siRNA (Life Technologies, Carlsbad, CA, USA); and Control siRNA: 81 UAAGGCUAUGAAGAGAUAC were all obtained. Co-culture A 1:1 ratio of cancer cells to MSCs were plated in Boyden Chamber (Corning Inc, Corning, NY, USA) wells with 0.4-μm pores that allow cytokine and growth factor passage but prevent cell movement.
Adhesion and invasion assays
Adhesion assays were performed on 96-well plates coated with 10 μg/ml Matrigel. Cells were trypsinized and re-suspended in Dulbecco's modified Eagle's medium with 1% bovine serum albumin, 1 mM MgCl 2 and 0.5 mM CaCl 2 at 1 × 10 6 cells/ml. In all, 1 × 10 5 cells (100 μl) were added per well and incubated for 30 min at 37°C in 5% CO 2 . Non-adherent cells were removed (phosphate-buffered saline wash with 1 mM MgCl 2 and 0.5 mM CaCl 2 ). Adherent cells were fixed with 3.7% paraformaldehyde, rinsed with phosphate-buffered saline and stained with 0.4% crystal violet. The dye was released by addition of 30% acetic acid, and the plates were read in a microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 590 nm. For invasion assays, cells were seeded at 10 5 cells per well in the upper chamber of 12-well Boyden Chamber transwells (8-μm pore). After incubation, cells on the top surface of filters were removed with cotton swabs. Adherent cells were fixed, dyed and measured as described above.
Quantitative real-time PCR
qRT-PCR was performed with the two-step reaction protocol using iQ SYBR Green Detection Kit (Bio-Rad Laboratories, Hercules, CA, USA). First-strand cDNA were synthesized from 1.0 μg of total RNA using the iScript Select cDNA Synthesis Kit (Bio-Rad Laboratories). Reaction protocol was: 25°C for Primer sequences SMA 5′-TAGCACCCAGCACCATGAAGAT-3′; 5′-GAAGCATTTGCGGTGGACA ATG-3′; Vimentin 5′-AGAACGTGCAGGAGGCAGAAGAAT-3′; 5′-TTCCATTTC ACGCATCTGGCGTTC-3′; Tenascin-C 5′-AGCATCACCCTGGAATGGAGGA-3′; 5′-TGTGGCTTGTTGGCTCTTTGGA-3′; FSP-1 5′-TGTCCTGCATCGCCATGATGT GTA-3′; 5′-TGAACTTGCTCAGCATCAAGCACG-3′; TGF-β1 5′-TGGCGATACCT CAGCAACC-3′; 5′-CTCGTGGATCCACTTCCAG-3′; MZF1 5′-AGTGTAAGCCCTC ACCTCC-3′; 5′-GGGTCCTGTTCACTCCTCAG-3′; and β-actin 5′-AGAGGGAA ATCGTGCGTGAC-3′; 5′-CAATAGTGATGACCTGGCCGT-3′.
Enzyme-linked immunosorbent assay
Supernatants were analyzed using TGF-β enzyme-linked immunosorbent assays (R&D Systems). Measurement of the active form required no manipulation; total protein measurement required acidification (1 N HCl followed by 1.2 N NaOH/0.5 M HEPES) prior to assay.
Construction of promoter plasmids
Human genomic DNA was isolated from normal human lung fibroblasts (ATCC CCL-210). TGF-β1 promoter region was defined using NCBI Reference Sequence NM_000660.4. Full-length promoter (−3360/+124) and deletion constructs (−1196/+124; − 691/+124; − 624/+124; − 551/+124; − 220/+124) were generated by PCR, setting the ATG start site as 0. All promoter fragments were cloned into pGL4.10(luc2) vectors (Promega, Madison, WI, USA) to generate luciferase-reporter constructs.
Construction of promoter mutations
Point mutations of the TGF-β1 promoter MZF1 putative-binding site were made using the QuikChange II Site Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). These mutated promoter fragments were cloned into pGL4.10(luc2) vectors, and direct sequencing analysis was confirmed.
Dual luciferase reporter assay
Four microgram of the luciferase-reporter constructs or empty pGL4.10 (luc2) vector were co-transfected with 0.4 μg of Renilla into MSCs and treated with OPN. After 48 h, using a Dual-Luciferase assay system (Promega), cells were lysed, and the promoter activity was measured as a ratio of Firefly:Renilla luciferase using the Modulus Luminometer (Promega).
ChIP RT-PCR Cells were treated with OPN and cultured for 48 h prior to DNA crosslinking and lysis. Chromatin was fixed and immunoprecipitated using the EZ-ChIP Assay Kit (EMD Millipore). For the RNA Polymerase II ChIP assay, purified chromatin was immunoprecipitated using 1 μg of RNA Polymerase Ab or normal mouse IgG (negative control). For the MZF1 ChIP assay, chromatin was immunoprecipitated using 1 μg of MZF1 Ab, RNA Polymerase Ab (positive control) or normal rabbit IgG (negative control). DNA was sonicated to 500-bp fragments. After DNA purification, RNA polymerase II binding to the TGF-β1 TATA box and final exon and MZF1 binding to the putative site on the TGF-β1 promoter was determined by qRT-CPR. CT values were normalized to β-actin. Products from qRT-PCR were run on agarose gel to visualize bands. ChIP RT-PCR primers were: TATA box: F 5′-CCCAGCCTGACTCTCCTTCCGTTC-3′; R 5′-GGTGATCCAGATG CGCTGTGGCTT-3′; Final exon: F 5′-GGTGGAGCAGCTGTCCAACATGAT-3′; R 5′-GCACGGGTGTCCTTAAATACAGCC-3′; and MZF1: F 5′-GAGCTCGCCCCA GAGTCTGAG-3′; R 5′-CGCGCCTCCGGCTCGCAGCGG-3′.
Zymography
Gelatin zymography used the Novex Zymogram Gel (Life Technologies) system. Concentrated serum-free Minimum Essential Medium α collected from MSC cultures was mixed with sample buffer and loaded on 10% gel. After running for 1.5 h, the gel was incubated in renaturing buffer for 30 min at room temperature. After incubating the gel with developing buffer at 37°C overnight, the gel was stained, and the images were acquired by AlphaImager 3400 (Protein Simple, Santa Clara, CA, USA).
Mouse xenograft model
Loyola University's Animal Care and Use Committee approved the animal protocols. Six-week-old female NOD-scid mice (Jackson Laboratory, Bar Harbor, ME, USA) were implanted with 10 6 dual-labeled cancer cells and GFP-MSCs and injected with APT or MuAPT as previously described. 17 After administration of D-luciferin (150 mg/kg), anesthetized mice (intraperitoneal ketamine (75 mg/kg) and xylazine (10 mg/kg)) were imaged with the IVIS 100 Imaging System (PerkinElmer, Waltham, MA, USA). Bioluminescence is reported as the sum of detected photons/second from a constant region of interest. Baseline tumor volume was established at day 2. Prior to necropsy, D-luciferin was injected to perform ex vivo imaging of primary lung and liver tumors.
Fluorescence-activated cell sorting
Single-cell suspension was prepared as described. 82 Cells were sorted using BD FACSAriaIII (BD Biosciences, Franklin Lakes, NJ, USA). For GFP, cells were excited using a 488-nm laser, with emission collected through a 530/30 bandpass filter. For RFP, cells were excited using a 561-nm laser, with emission collected through a 610/20 bandpass filter.
Immunohistochemistry
Human breast cancer tissue samples (IRB approved) were formalin fixed, paraffin embedded, sectioned to 5 μm, rinsed and followed by antigen unmasking utilizing Leica ER2 (Leica Biosystems, Richmond, IL, USA) concentrated EDTA retrieval solution. Tissues were stained with OPN, TGF-β1, MZF1 and SMA antibodies using the modified Protocol F, staining was detected using Leica refine DAB kit, and slides were rinsed, counterstained, dehydrated and mounted.
Statistical analysis
All experiments were done in triplicate. Data are presented as mean ± s.d. Analysis utilized Student's t-tests and ANOVA. Values of Po0.05 were considered significant.
Please see supplementary information for more detailed methodology.
